Highlights from ACR Convergence 2022

Meeting Mic

In this episode of Meeting Mic, we bring you the highlights and insights from the ACR Convergence 2022, as well as Healio’s top headlines from the meeting. Alfred Kim, MD, discusses some key take-home points from the Long COVID presentation :18 Giovanni Adami, MD, reviews the impact of tofacitinib on fracture risk in patients with rheumatoid arthritis and the effect of glucocorticoids on bone density. 3:39 Leonard Calabrese, DO, gives a long-view of the meeting and the sessions he attended. 6:06 Paul Emery, MD, discusses results of a phase 2 study of peresolimab for adults with rheumatoid arthritis. 9:32 Read the full coverage here: https://www.healio.com/news/rheumatology/ 20221112/understanding- of-long-covid-shifting-at- breakneck-speed https://www.healio.com/news/rheumatology/ 20221122/bonesafe-glucocorticoid- dose-hard-to-find-in- rheumatic-musculoskeletal- diseases https://www.healio.com/news/rheumatology/ 20221121/pd1-agonist-generates-a-bit-of-excitement- in- rheumatoid- arthritis ACR: Varicella vaccine strongly recommended in all immunosuppressed adults ‘Anatomy inventory’ fosters more inclusive care for transgender, non-binary patients 'Strange times’: Prescribing methotrexate legally ‘low risk’ Post-Roe Disclosures: Adami reports consultant roles with Amgen, BMS, Eli Lilly, Fresenius Kabi, Galapagos, Theramex and UCB. Calabrese reports consultant roles with AstraZeneca and GSK. Emery reports relationships with AbbVie/Abbott, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, Galapagos, Gilead, Novartis, Pfizer, Roche and Samsung. Kim reports no relevant financial disclosures.